Adverse Events, Comorbidities, and HIV

July 29, 2021: Racial disparities in hospitalization rates; city-specific mortality demographics; effects of traditional risk factors vs. antiretrovirals on weight gain and cardiovascular risk.

July 22, 2021: How HIV criminalization laws may reduce disclosure; anxiety and housing satisfaction; poor immune response to delayed ART; the U.S.'s HIV testing mountain.

HIV status is a risk factor for worse COVID-19 outcomes, but it remains uncertain the extent to which antiretroviral therapy, viral load, and CD4 count can reduce that risk, according to a new flurry of research presented at IAS 2021.

The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.

Our quick summaries of breaking conference research include new study findings on injectable long-acting cabotegravir/rilpivirine and the latest on lenacapavir, a twice-yearly injectable medication in the pipeline.

July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.

Activism, research, and lessons learned from the AIDS epidemic are saving lives during the COVID-19 pandemic. They can also help lead the world toward herd immunity.

July 8, 2021: Trends among heavily treatment-experienced PLWH; a new look at peripheral neuropathy factors; heart transplantation in PLWH; complications following successful HCV treatment.

For mental health providers treating LGBTQ people—youth in particular—the past 18 months have brought new challenges into clear focus.

Like the treatment divide of the early HIV/AIDS crisis, the uneven distribution of COVID-19 vaccines poses a global threat.